The QCDx New Financing Round Is Closing By End of March 2025 - Contact Us To Receive Press Release
Leadership Team
Kathleen Adams is a healthcare and life sciences executive with extensive experience in marketing, new product development, and commercialization; her accomplishments have contributed to organizations ranging from Fortune 100 pharma companies and venture-backed diagnostics start-ups to a globally recognized academic research institution. Kate has a Bachelor’s in Biology and Philosophy from Bryn Mawr College and an MBA from the Yale School of Management. She was Product Manager for Intron A at Schering-Plough; Associate Director of New Business Development at Parke-Davis; Director of Oncology & Specialty Physician Marketing at Quest Diagnostics; served on the Board of Directors of Enterix, a privately held small diagnostics manufacturer; was VP of Marketing at HistoRx, a venture-backed start-up diagnostic firm sold to a Novartis subsidiary; and Program Director of Clinical Innovation at The Jackson Laboratory for Genomic Medicine. Before joining QCDx, Kate was advising start-up companies as an Entrepreneur-in-Residence at UCONN’s Technology Incubation Program.
Kathleen Q. Adams MBA, Chief Commercial Officer
Brian Ciarcia, Chief Information Officer
Brian is a 25+ year expert in cloud architecture with prior experience spanning from the US Military to the Healthcare Industry. He maintains a broad expertise in multiple software operating environments, with a special focus on security and compliance. In his career he has successfully reduced IT budgets by over 35%, increased the overall security footprint by 75%, and drastically increased staff efficiency in today's mobile workforce. Brian is Director of Information Technology for SoNE Health since 2021. Prior to that he was a partner at Aegis Information Systems (Rocky Hill, CT) managing network infrastructures for various industries, including non-profit, law firms and hospitals (2020-2021). Before that he served as IT Manager at Pepe & Hazard LLP, handling litigation support, cloud computing and document management (2000-2010). Prior to that he served a 4-year active duty in the U.S. Air Force, where he maintained a Top-Secret Clearance monitoring communications for the armed forces. Before that he served a 4-year Active Duty in the U.S. Army where he specialized in installation of military base fiber networks, as well as managing computer fleets.
Patrick Curry, Chief Financial Officer
Patrick has been in senior operational and financial management roles in venture backed technology companies for over 25 years, raising $200M+ venture capital for early-stage ventures. Prior to his role as CFO of QCDx, he was a founder and CFO/COO of CytoVeris, an oncologic surgical device developer, where he participated in raising $15M of private equity capital and managed clinical relationships as well as regulatory strategy. Prior to CytoVeris, he was President and General Manager of Expro Meters, in Wallingford CT, where he led the development and world-wide commercialization of cutting-edge technology solutions to monitor hydrocarbon production. Patrick has been CFO of several venture backed companies, including Protedyne (acquired by LabCorp), which developed robotic automation solutions for the pharmaceutical and biotech industries. Patrick has also served as CFO of Novalux, a semiconductor laser start-up, Perimeter Networks, a cloud-based email and network security solutions provider (acquired by BAE), Digital Graphix and Safeway Disposal Systems (acquired by Stericycle). He was also a partner in NorthEast Ventures, a venture capital/advisory firm, and is a CPA. He earned a B.A. in Economics from Bates College and a M.A. in Business from the University of Hartford.
David Fournier, Chief Engineering Officer
David Fournier is an engineering leader with 30+ years in lasers and electro-optics, successfully bringing new technologies from concept to market. David most recently worked for CytoVeris corporation, as VP of optics and systems integration working on a novel fluorescence imaging system, using AI to indicate areas of interest. He was an early leader of Quanterix Corp, now of Billerica, MA, where his engineering team brought the first fully automated, immuno-assay, single molecule Array (SiMoA) instrument to the RUO market. His career in biotechnology began twenty-four years ago when he joined Cyvera corporation, a venture backed startup bringing a new encoded particle system for assay development to market. That company was purchased by Illumina corp, where he continued to work for an additional three years before joining Quanterix. Prior to his work in biotech, David was an electro-optics engineer for Cidra Corporation, Gerber systems Corp and Agfa where he was instrumental in designing products for the telecommunications, oil & gas, printed circuit board and printing industries. David is a named inventor on more than 25 patents, he holds a BS degree and an MS degree in electrical engineering, specializing in electro-optics from the university of Massachusetts, Lowell.
Kenneth I Kaitin PhD, Director
Kenneth Kaitin is a Professor at Tufts University School of Medicine and Senior Fellow at Tufts Center for the Study of Drug Development. He is also Advisory Professor at Shanghai Medical College at Fudan University and serves on the faculty of the European Center for Pharmaceutical Medicine at the University of Basel. Dr. Kaitin is internationally recognized for contributions to the fields of drug development policy and science. He consults, speaks, and writes on global trends in pharmaceutical development, and he has provided public testimony before the U.S. Congress. A former President of the Drug Information Association, Dr. Kaitin recently served as Editor-in-Chief of Expert Review of Clinical Pharmacology, and as a consultant to the U.S. Department of Defense on bioterror countermeasures. In 2011, he received the Dr. Louis M. Sherwood Award, granted by the Academy of Pharmaceutical Physicians and Investigators; in 2020 he was named Global Fellow in Medicines Development by the International Federation of Pharmaceutical Physicians, and in 2021 he received the Distinguished Achievement Award from the Sino-American Pharmaceutical Professionals Association (SAPA). Dr. Kaitin is a director on the boards of Curis, Inc. (NASDAQ: CRIS), Bio-Tree Systems, Inc., and QCDx. He earned his BS from Cornell University and MS and PhD in pharmacology from the University of Rochester.
Fahmy has 10+ years of professional experience in academia, clinical, and industrial settings. In addition to his expertise in oncology medical communications, Dr. Mamuya has a strong background in high-end research imaging gained from his biomedical research studies and his roles as a research imaging specialist within the microscopy industry. He received a Ph.D. in Cells, Organs, and System Physiology from the University of Delaware. He studied epithelial cell behavior after injury/surgery and showed excellent potential for secondary cataract therapeutics that are currently under development. Dr. Mamuya continued his academic research career as a Post-Doctoral Fellow at Massachusetts General Hospital and Harvard Medical School and published his work on integrin receptors' critical roles in kidney development and function. He holds an MBA from the University of Delaware and is Adjunct Professor at Bay Path University Master's program in Applied Laboratory Science & Operations.
Fahmy A Mamuya PhD MBA, Director, Research & Development
Triantafyllos (Fyl) Tafas PhD, Founder, CEO & Director
Fyl is a Life Sciences entrepreneur and developer of precision diagnostics aiming to transform human health. He founded QCDx in 2017 to develop and commercialize a next-generation rare cell detection technology, by leading a multi-disciplinary team, working at the intersection of genomics, optics, microfluidics, and big data. He co-founded Ikonisys Inc. in 2000 and served as the CSO, CTO and then President a robotic microscopy platform and diagnostic products used by major clinical customers in the US and Europe to deliver more than 300,000 cancer diagnostic tests. Prior to that, he developed a new prenatal Down screening biomarker which was licensed to Chromavision (Clarient Inc. /Neogenomics) and introduced the first Prenatal Chromosomal Abnormalities Screening Program for Greece. He co-authored more than seventy publications and is the co-inventor to 38 US patents and multiple patents pending. He was awarded the prestigious Jefferson Medal Award by the New Jersey Intellectual Property Law Association and the Distinguished Services Award from the University of Athens, Greece. He is holding a B.S. in biology and Ph.D. in ecology and populations biology from the University of Athens.
Andreas Typaldos, Director
Mr. Typaldos is a veteran and pioneer software and technology entrepreneur, as well as founder and/or owner of businesses in the hospitality and other commercial areas. He has been founder and founding or early investor of a number of software and technology companies in the US and Europe through a Typaldos Family Office. He has deep and broad management and enterprise development experience, with expertise and international and financial contacts, over a wide range of industries. He is CEO of Xandros Inc. He co-founded Cogia GMBH (Frankfurt, DE). He is the major shareholder of CoinAnalyst. He is Executive Chairman of Bridgeways Inc and Chairman of Arkados Group Inc. He is the founder, CEO, and venture partner of the Kerna Group, and Chairman or CEO of a number of Group companies. He is Chairman and CEO of Scalix Corporation. He is holding a BS in Mathematical Methods for Engineering and Operations from Columbia University and a Masters in Computer Science from Pratt Institute.
Paul C White, Director
Paul White has 25+ years as a senior executive with diverse industry experience including healthcare, media and high tech. Mr. White currently runs a boutique consulting firm focused on driving profitable growth, where he serves as a senior advisor to PE firms and private companies.
Paul began his career as a CPA and business consultant for two “big six” firms (now Accenture and EY), and then began a journey as a “serial CFO and business leader”. From 2020 to 2021 he was the CFO of Hunter Quinn Homes, where he positioned the company for 3-4X growth. From 2014 to 2019 he served as SVP of Business Transformation for Outfront Media, a $2B public advertising company where his efforts created $100M+ in recurring, bottom-line profits. From 2012 to 2014 he served as VP in charge of the video business of Frontier Communications, a $200B telecom, where he grew that unit by 3X. From 2010 to 2012 he was CFO of EJ Electric, the largest Electrical Contractor in NYC, where he helped grow the company by 260%. From 2006 to 2010 he served as first CFO and then President of Ikonisys, helping to transition from pre-revenue to revenue producing and raising $50M+ along the way. From 2000 to 2006 he served as CFO of Deltathree, a public VOIP Pioneer which he helped drive to a profitable, white-label provider to the largest telecoms. Mr. White earned both his BBA and MBA a Hofstra University.
Seth Winfree PhD, Chief Scientific Officer
Dr. Winfree is an accomplished scientist with over 20 years of research experience, specializing in immunology, nephrology, cancer biology, and advanced microscopy. He holds a Ph.D. in Cellular & Integrative Physiology with a minor in Business of Life Sciences from Indiana University School of Medicine, where he studied neutrophil diversity in ischemic acute kidney injury using advanced imaging, single-cell, and spatial transcriptomics under Dr. Tarek M. El-Achkar. His postdoctoral research in cancer immunology was conducted at the University of Nebraska Medical Center with Dr. Tony Hollingsworth.
Dr. Winfree served as Assistant Professor with a funded research program at the University of Nebraska Medical Center, held multiple roles at NIH-NIAID’s Rocky Mountain Laboratories, and positions at Indiana University School of Medicine. He has significantly contributed to major NIH-funded initiatives, including the Kidney Precision Medicine Project, the Human Biomolecular Atlas Program, and the O’Brien Kidney National Resource Centers. Dr. Winfree has developed innovative imaging methodologies and machine learning tools aimed at advancing precision medicine. His extensive work is documented through numerous high-impact scientific publications.